Medical Devices and Technologies
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities
Our team spans disciplines including intellectual property (contentious and non-contentious), regulatory, product liability, mergers and acquisitions, commercial transactions (including licensing and collaborations), and capital markets and finance matters.
Our international network ensures that we have a ready resource of expertise in a wide range of jurisdictions and that we are well positioned to advise on cross-border work. Our lawyers have been advising clients in the sector for many years and have developed a deep understanding of the issues affecting the industry. This ensures that we add value to any matter and there is no learning curve.
For example, our team has been closely following the current proposed changes to the European medical devices regulatory framework. We have also been tracking and advising our clients on regulatory issues in the context of emerging technologies such as device/drug combinations, medical apps and other “connected health” initiatives. In these areas we use our broad and interdisciplinary experience to help our clients navigate what may often be rapidly evolving or uncertain regulatory pathways and manage the risks of new product development.
News and insights
Blog Post: 05 October 2023
Companion diagnostics are classed in the U.S. and in the EU as medical devices, usually in-vitro medical devices (IVDs).
News: 28 September 2023
Enovis™ Corporation (NYSE: ENOV, “Enovis”), an innovation-driven, medical technology growth company, has announced a definitive agreement to acquire LimaCorporate S.p.A. (“Lima”) from EQT Private…
Blog Post: 22 September 2023
The regulatory frameworks for medicines and medical devices have historically grown up on separate tracks, but increasingly, medicines and medical devices are being used together in patients as drug…
Blog Post: 18 July 2023
The Medicines and Healthcare products Regulatory Agency recently published a Corporate Plan outlining their strategic priorities for the next three years. A key area of focus is international…